Xeris Biopharma rises on report Lundbeck interest in takeover
Xeris Biopharma shares rose 2.8% to $10.08 after Bloomberg reported Lundbeck A/S expressed interest in acquiring the company, citing people familiar with the matter; Lundbeck and Xeris did not respond to Reuters requests for comment.
Shares of Xeris Biopharma gained 2.8% to $10.08 after Bloomberg News reported that Lundbeck A/S has expressed interest in acquiring the company, citing people familiar with the matter. The report said the Danish pharmaceuticals company has been working with advisers to explore a takeover of Chicago-based Xeris. Lundbeck and Xeris Biopharma did not immediately respond to Reuters requests for comment. Up to the previous close, XERS was up 27.9% year to date.